Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
February 12, 2024Leukemia & lymphoma/Leukemia and lymphomaOpen Access

A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

IMIsha MolYHYannan HuTLThomas W. LeBlanc

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mol et al. (2024) studied this question.

synapsesocial.com/papers/68e796e3b6db643587707cf8https://doi.org/10.1080/10428194.2024.2313628
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy2026
  2. 2Prognostic Factors Influencing the Efficacy and Safety of Teclistamab and Elranatamab in Multiple Myeloma: A Multicenter Propensity-Weighted Analysis2026 · 1 citations
  3. 3Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma2024 · 17 citations
  4. 4Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).2024 · 1 citations
  5. 5Elranatamab: Mechanism of Action, Clinical, and Translational Science.2026